HR+ Early Breast Cancer

Authored by Ilana Schlam, published on 2026-08-22 00:09:19.0

The algorithm is broadly aligned with contemporary management of HR+/HER2- early breast cancer, especially the use of genomic assays (Oncotype DX) to guide adjuvant chemotherapy decisions and the incorporation of adjuvant CDK4/6 inhibition and PARP inhibition for selected high-risk populations. It appropriately distinguishes node-negative vs node-positive disease and menopausal status effects on chemotherapy benefit in node-positive patients. Some elements are underspecified (radiation indications, endocrine regimen selection/duration) and a few decision points are simplified (e.g., premenopausal RS 16–25 node-negative and the framing of chemotherapy vs OFS+AI in RxPONDER-eligible premenopausal patients). The added note to use adjuvant bisphosphonates in postmenopausal early-stage disease is consistent with major guidelines and meta-analyses.

  1. HR+ early stage
    *FOR SELECTED PATIENTS: BRCAwt Abemaciclib - MonarchE (2y, 4+ LN or 1-3 LN + G3 or 5+ cm) Ribociclib – NATALEE (3y, stage 2A if N1 or N0+high risk, 2B, 3**) gBRCAm Olaparib - OlympiA (1y, T2 or 4+ LN)
    • Node negative
      TailorX 2018, 2019
      • Surgery
        • Premenopausal
          • RS 1-15
            * lidERA: giradestrant vs ET in stage 1-3 disease
            • Endocrine therapy
          • RS 16-25
            • Some may benefit from chemotherapy (TC, ddAC-T)
              • Endocrine therapy
          • RS 26+
            • Chemotherapy (TC, ddAC-T)
              • Endocrine therapy
        • Postmenopausal
          Add adjuvant Zometa for 2-3 years for postmenopausal early-stage disease (q6 months for 2-3 years).
          • RS 1-25
            • Endocrine therapy
          • RS 26+
            • Chemotherapy
              • Endocrine therapy
    • Positive LN*
      * Consider Prosigna (per OPTIMA) vs Oncotype for node positive patients (especially in premenopausal (40+), node positive)
      • 1-3 LN
        RxPonder
        • Surgery
          • Premenopausal
            • RS 1-25
              • Chemotherapy vs OFS + Al
                • Endocrine therapy
            • RS 26+
              • Chemotherapy (TC, ddAC-T)
                • Endocrine therapy
          • Postmenopausal
            Add adjuvant Zometa for 2-3 years for postmenopausal early-stage disease (q6 months for 2-3 years)
            • RS 1-25
              • Endocrine therapy
            • RS 26+
              • Chemotherapy (TC, ddAC-T)
                • Endocrine therapy
      • 4+ LN**
        ** For patients with 4+ Lymph nodes and/IBC/large tumors excluded from consider chemotherapy vs genomic assay from biopsy to guide treatment
        • Surgery
          • Chemotherapy (ddAC-T>TC)
            • Endocrine therapy
  2. FOR SELECTED PATIENTS
    Postmenopausal => Add adjuvant Zometa for 2-3 years for postmenopausal early-stage disease (q6 months for 2-3 years) Stage 2A if N1 or NO G3 or NO G2 + Ki67 >20%, high risk genomic score, 2B, 3 (different eligibility for MonarchE, NATALEE and OLYMPIA): BRCAWt => Abemaciclib - MonarchE (2y, 4+ LN or 1-3 LN + G3 or 5+ cm) BRCAWt => Ribociclib - NATALEE (3y, stage 2A if N1 or NO+high risk, 2B, 3**) gBRCAm => Olaparib - OlympiA (1y, 2 or 4+ LN)
tosprivacyAbemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Ribociclib plus Endocrine Therapy in Early Breast CancerAdjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast CancerAdjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerA Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer